Congress quietly expands drug compounding to bypass shortages—with minimal FDA oversight

What it does

This bill expands pharmacy compounding rules to allow pharmacists and physicians to make copies of drugs in short supply without a specific patient prescription, provided they follow strict tracking and reporting requirements. It also strengthens FDA reporting rules for drug shortages and surges in demand, requiring manufacturers to notify the agency sooner and more completely.

Why we flagged it

The bill's core function is to create a regulatory carve-out for emergency compounding during drug shortages while simultaneously tightening FDA reporting and tracking requirements. It is a public-health measure, not a corporate giveaway or vanity provision.

What the text implies

• Compounding pharmacies and outsourcing facilities gain new revenue streams from emergency shortage compounding, potentially creating financial incentives to tolerate or underreport shortages.
• The 60-day lookback window for shortage status may allow compounding to continue even after a shortage officially ends, creating a lag in market reversion.
• Tracking and reporting burdens fall on hospitals and clinical settings, which must collect and return patient data within 7 days—a compliance cost not explicitly funded.
• The bill does not cap the quantity of compounded drugs a pharmacy can distribute, potentially allowing large-scale production under the 'urgent administration' exemption.

Who it affects

Patients facing drug shortages gain faster access to needed medications through emergency compounding, while new transparency and tracking requirements reduce safety risks. The bill does not appear to create new costs for ordinary people or shift burdens to the public.

Who stands to gain

• pharmacy compounding services
• outsourcing facilities (503B)
• specialty pharmaceutical manufacturers

Named in the bill

FDA, Food and Drug Administration, MedWatch, Section 503A, Section 503B, Section 506C, Section 506E, US Pharmacopeia, licensed pharmacists, licensed physicians, outsourcing facilities, drug shortage list

Where it stands

3 cosponsors: 3 Republicans.

• Sep 11, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 11, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 7 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $820,000 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Diana Harshbarger, the sponsor, reported $727,520 in PAC receipts in the 2026 cycle.

• Professional Compounding Centers of America — $360,000 on 2 filings
• National Community Pharmacists Association — $270,000 on 1 filing
• Eli Lilly and Company Fka Lilly Usa, LLC — $100,000 on 2 filings
• Alliance for Pharmacy Compounding — $50,000 on 1 filing
• Independent Pharmacy Cooperative — $40,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.